INCYTE CORPORATION (INCY) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-03-31..
Gross margin
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 5.36B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-03-31 | (m) | $5.36B | (m) | (m) |
| 2025-12-31 | (m) | $5.14B | (m) | (m) |
| 2025-09-30 | (m) | $4.81B | (m) | (m) |
| 2025-06-30 | (m) | $4.58B | (m) | (m) |
| 2025-03-31 | (m) | $4.41B | (m) | (m) |
| 2024-12-31 | (m) | $4.24B | (m) | (m) |
| 2024-09-30 | (m) | $4.08B | (m) | (m) |
| 2024-06-30 | (m) | $3.86B | (m) | (m) |
| 2024-03-31 | (m) | $3.77B | (m) | (m) |
| 2023-12-31 | (m) | $3.70B | (m) | (m) |
| 2023-09-30 | (m) | $3.61B | (m) | (m) |
| 2023-06-30 | (m) | $3.51B | (m) | (m) |
| 2023-03-31 | (m) | $3.47B | (m) | (m) |
| 2022-12-31 | (m) | $3.39B | (m) | (m) |
| 2022-09-30 | (m) | $3.33B | (m) | (m) |
| 2022-06-30 | (m) | $3.32B | (m) | (m) |
| 2022-03-31 | (m) | $3.11B | (m) | (m) |
| 2021-12-31 | (m) | $2.99B | (m) | (m) |
| 2021-09-30 | (m) | $2.91B | (m) | (m) |
| 2021-06-30 | (m) | $2.72B | (m) | (m) |
| 2021-03-31 | (m) | $2.70B | (m) | (m) |
| 2020-12-31 | (m) | $2.67B | (m) | (m) |
| 2020-09-30 | (m) | $2.46B | (m) | (m) |
| 2020-06-30 | (m) | $2.39B | (m) | (m) |
| 2020-03-31 | (m) | $2.23B | (m) | (m) |
| 2019-12-31 | (m) | $2.16B | (m) | (m) |
| 2019-09-30 | (m) | $2.11B | (m) | (m) |
| 2019-06-30 | (m) | $2.01B | (m) | (m) |
| 2019-03-31 | (m) | $2.00B | (m) | (m) |
| 2018-12-31 | (m) | $1.88B | (m) | (m) |
| 2018-09-30 | (m) | $1.80B | (m) | (m) |
| 2018-06-30 | (m) | $1.73B | (m) | (m) |
| 2018-03-31 | (m) | $1.53B | (m) | (m) |
| 2017-12-31 | (m) | $1.54B | (m) | (m) |
| 2017-09-30 | (m) | $1.42B | (m) | (m) |
| 2017-06-30 | (m) | $1.31B | (m) | (m) |
| 2017-03-31 | (m) | $1.23B | (m) | (m) |
| 2016-12-31 | (m) | $1.11B | (m) | (m) |
| 2016-09-30 | (m) | $1.02B | (m) | (m) |
| 2016-06-30 | (m) | $941.24M | (m) | (m) |
| 2016-03-31 | (m) | $857.94M | (m) | (m) |
| 2015-12-31 | (m) | $753.75M | (m) | (m) |
| 2015-09-30 | (m) | $633.84M | (m) | (m) |
| 2015-06-30 | (m) | $644.38M | (m) | (m) |
| 2015-03-31 | (m) | $580.98M | (m) | (m) |
| 2014-12-31 | (m) | $511.50M | (m) | (m) |
| 2014-09-30 | (m) | $484.59M | (m) | (m) |
| 2014-06-30 | (m) | $371.57M | (m) | (m) |
| 2014-03-31 | (m) | $373.66M | (m) | (m) |
| 2013-12-31 | (m) | $354.95M | (m) | (m) |
| 2013-09-30 | (m) | $371.72M | (m) | (m) |
| 2013-06-30 | (m) | $347.09M | (m) | (m) |
| 2013-03-31 | (m) | $331.96M | (m) | (m) |
| 2012-12-31 | (m) | $297.06M | (m) | (m) |
| 2012-09-30 | (m) | $212.10M | (m) | (m) |
| 2012-06-30 | (m) | $168.39M | (m) | (m) |
| 2012-03-31 | (m) | $98.66M | (m) | (m) |
| 2011-12-31 | (m) | $94.45M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $169.88M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $9.27M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |